Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer – A Case Report

QR Code

Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer – A Case Report

Yuanxiang Li,&ast; Yang Hu,&ast; Bin Yang, Caibao Jin, Hui Ren, Jingyi Wu, Zhijun Wang, Youying Wei, Ling Yang, Yanping Hu Department of Oncology, Hubei Cancer Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, 430079, Hubei, People’s Republic of China&am...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Li Y, Hu Y, Yang B, Jin C, Ren H, Wu J, Wang Z, Wei Y, Yang L
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2021
Sujets:	pd-1/pd-l1 inhibitors immune-related cardiotoxicity non-small cell lung cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/bad2ceccf85643c5801d75cad0079802
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report
par: Albina S. Zhabina, et autres
Publié: (2021)

Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China
par: Jiamin Sheng, et autres
Publié: (2021)

Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives
par: Denis I. Yudin, et autres
Publié: (2021)

The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
par: Nikolai A. Ognerubov, et autres
Publié: (2021)

Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives
par: Inoue H, et autres
Publié: (2020)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
par: Zou W, et autres
Publié: (2021)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
par: Zago G, et autres
Publié: (2016)

The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?
par: Vladislav O. Sarzhevskiy, et autres
Publié: (2021)

Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy
par: Shubin Chen, et autres
Publié: (2021)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
par: Utpal Kumar, et autres
Publié: (2021)

Prognostic implication of PD‐L1 polymorphisms in non‐small cell lung cancer treated with radiotherapy
par: Min Kyu Kang, et autres
Publié: (2021)

Immunotherapeutic Advances for NSCLC
par: Massafra M, et autres
Publié: (2021)

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
par: He Ba, et autres
Publié: (2021)

Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer
par: Yu Chen, et autres
Publié: (2021)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
par: Yixi Zhang, et autres
Publié: (2021)

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
par: Xin Cai, et autres
Publié: (2021)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
par: Nathaniel Wiest, et autres
Publié: (2021)

Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
par: Yahua Wu, et autres
Publié: (2022)

A cellular census of human peripheral immune cells identifies novel cell states in lung diseases
par: Dongli Song, et autres
Publié: (2021)

Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
par: Virginia Liberini, et autres
Publié: (2021)

A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer
par: Jianyuan Zhou, et autres
Publié: (2021)

Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review
par: Jinhan Zhou, et autres
Publié: (2021)

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
par: Yuanfang Xin, et autres
Publié: (2021)

Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates
par: Shijie Shang, et autres
Publié: (2021)

CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy
par: Jean-Marie Michot, et autres
Publié: (2021)

Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling
par: Jiang Q, et autres
Publié: (2021)

Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
par: Galina B. Statsenko, et autres
Publié: (2020)

Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
par: Mina LA, et autres
Publié: (2020)

Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
par: YU Xuxu, et autres
Publié: (2021)

Oligoprogression in Non-Small Cell Lung Cancer
par: Daijiro Harada, et autres
Publié: (2021)

Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer
par: Limei Wang, et autres
Publié: (2021)

Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction
par: A. V. Chetveryakov, et autres
Publié: (2021)

Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters
par: Gaurav Garg, et autres
Publié: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
par: Zhitao Li, et autres
Publié: (2021)

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
par: Seetharamu N, et autres
Publié: (2017)

Case Report: Response With Immunotherapy in a Patient With Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gallbladder
par: Chao Liu, et autres
Publié: (2021)

Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2
par: Damian Mojsak, et autres
Publié: (2021)

Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy
par: Chenlu Li, et autres
Publié: (2021)

Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
par: Kimberly M. Burcher, et autres
Publié: (2021)

Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
par: Wang J, et autres
Publié: (2021)